{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:43:42Z","timestamp":1793979822599,"version":"4.8.0"},"reference-count":603,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:p>The British Association for Psychopharmacology guidelines for the management of substance dependence focus primarily on the pharmacological aspects of treatment. A group of international experts from a wide range of disciplines reviewed the current evidence in their field, considered the strength of the evidence and discussed the clinical implications at a consensus meeting. The guidelines focus on the pharmacological management of dependence on alcohol, benzodiazepines, \u2018z-drugs\u2019, \u03b3-hydroxybutyrate (GHB), gabapentinoids, opioids, nicotine, cannabis and synthetic cannabinoids, cocaine, amphetamine and methamphetamine, dissociative drugs and their analogues. They are based on the available evidence and make recommendations to aid clinical decision making, as well as highlighting the gaps in the current evidence-base.<\/jats:p>","DOI":"10.1177\/02698811251399593","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T06:35:33Z","timestamp":1771914933000},"page":"227-272","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":10,"title":["Evidence-based consensus guidelines for the pharmacological management of substance dependence: Recommendations from the British Association for Psychopharmacology"],"prefix":"10.1177","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1905-2025","authenticated-orcid":false,"given":"Julia M. A.","family":"Sinclair","sequence":"first","affiliation":[{"name":"Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3820-9243","authenticated-orcid":false,"given":"Nicola J.","family":"Kalk","sequence":"additional","affiliation":[{"name":"Department of Addictions, Institute of Psychiatry, Psychology and Neuroscience, King\u2019s College London, London, UK"},{"name":"South London and Maudsley NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0194-0806","authenticated-orcid":false,"given":"Stephen J.","family":"Kaar","sequence":"additional","affiliation":[{"name":"Division of Psychology and Mental Health, School of Health Sciences, Faculty of Biology, Medicine, and Health, The University of Manchester, Manchester, UK"},{"name":"Greater Manchester Mental Health NHS Foundation Trust, Addictions Services, Chapman-Barker Unit Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7395-6845","authenticated-orcid":false,"given":"Roberta","family":"Agabio","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Section of Neurosciences and Clinical Pharmacology, University of Cagliari, Cagliari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini","family":"Arunogiri","sequence":"additional","affiliation":[{"name":"Turning Point, Eastern Health, Melbourne, VIC, Australia"},{"name":"Monash University, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Bisaga","sequence":"additional","affiliation":[{"name":"Columbia University College of Physicians and Surgeons, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2851-5252","authenticated-orcid":false,"given":"Edward","family":"Chesney","sequence":"additional","affiliation":[{"name":"Department of Addictions, Institute of Psychiatry, Psychology and Neuroscience, King\u2019s College London, London, UK"},{"name":"South London and Maudsley NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Daly","sequence":"additional","affiliation":[{"name":"Greater Manchester Mental Health NHS Foundation Trust, Addictions Services, Chapman-Barker Unit Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5654-749X","authenticated-orcid":false,"given":"Jonathan","family":"Dewhurst","sequence":"additional","affiliation":[{"name":"Addiction and Homeless Services, Greater Manchester Mental Health NHS Foundation Trust, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom P.","family":"Freeman","sequence":"additional","affiliation":[{"name":"Addiction and Mental Health Group, Department of Psychology, University of Bath, Bath, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0988-7694","authenticated-orcid":false,"given":"Abhishek","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Postgraduate Institute of Medical Education &amp; Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4476-2475","authenticated-orcid":false,"given":"Sophia","family":"Hemrage","sequence":"additional","affiliation":[{"name":"Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Leggio","sequence":"additional","affiliation":[{"name":"Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA"},{"name":"Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Lingford-Hughes","sequence":"additional","affiliation":[{"name":"Imperial College London, London, UK"},{"name":"Central North West London NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catriona","family":"Matheson","sequence":"additional","affiliation":[{"name":"University of Stirling, Stirling, Scotland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"McKetin","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9137-4419","authenticated-orcid":false,"given":"Louise M.","family":"Paterson","sequence":"additional","affiliation":[{"name":"Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmert","family":"Roberts","sequence":"additional","affiliation":[{"name":"Department of Addictions, Institute of Psychiatry, Psychology and Neuroscience, King\u2019s College London, London, UK"},{"name":"South London and Maudsley NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5296-3181","authenticated-orcid":false,"given":"Deborah","family":"Robson","sequence":"additional","affiliation":[{"name":"Department of Addictions, Institute of Psychiatry, Psychology and Neuroscience, King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4920-0914","authenticated-orcid":false,"given":"Jenny","family":"Scott","sequence":"additional","affiliation":[{"name":"Bristol Medical School, University of Bristol, Bristol, UK"},{"name":"Connect (Turning Point Drug &amp; Alcohol Service), Wiltshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Welch","sequence":"additional","affiliation":[{"name":"Addiction Psychiatrist (retired), Gloustershire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2017.01.013"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/dar.13511"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1159\/000433579"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008581.pub2"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(18)30303-1"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012557.pub3"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107454"},{"issue":"259","key":"e_1_3_3_9_1","first-page":"1","article-title":"Comparing the effect of buprenorphine and methadone in the reduction of methamphetamine craving: A randomized clinical trial","volume":"18","author":"Ahmadi J","year":"2017","unstructured":"Ahmadi J, Razeghian Jahromi L (2017) Comparing the effect of buprenorphine and methadone in the reduction of methamphetamine craving: A randomized clinical trial. Trials 18(259): 1\u20138.","journal-title":"Trials"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2710.2001.00325.x"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1071\/HC21011"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/alcalc\/agad021"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/15504263.2010.537515"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2710.2000.00295.x"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103877"},{"key":"e_1_3_3_16_1","first-page":"1","author":"All Wales Medicines Strategy Group","year":"2023","unstructured":"All Wales Medicines Strategy Group (2023) Polypharmacy in older people: 1-42.","journal-title":"Polypharmacy in older people"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.1992.tb00695.x"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2011.06.003"},{"key":"e_1_3_3_19_1","unstructured":"Alvanzo A Kleinschmidt K Kmiec JA et al (2020) The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management. Available at: http:\/\/links.lww.com\/JAM\/A192 (accessed 21 June 2025)."},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2024.0709"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2012.12.013"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.31264"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2021.108518"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005063.PUB3"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008537.pub2"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003409.pub4"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2009.02549.x"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15798"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.17.2003"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10101436"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.0249"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010274.pub2"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11469-023-01078-y"},{"key":"e_1_3_3_35_1","first-page":"1","article-title":"The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update","volume":"14","author":"ASAM","year":"2020","unstructured":"ASAM (2020) The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update. Journal of Addiction Medicine 14: 1\u201391.","journal-title":"Journal of Addiction Medicine"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-3-16"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/10550880802122596"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001359"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.35478"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.12809"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011481.pub2"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cobeha.2016.09.007"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.15853"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.111018"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.15695"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.2147\/nedt.2007.3.2.185"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2022.07.009"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881115598411"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2009.03.021"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1080\/00952990802342899"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001422"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2022.2028802"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900011202"},{"issue":"2","key":"e_1_3_3_54_1","first-page":"108","article-title":"Impact of slow-release oral morphine on drug abusing habits in Austria","volume":"24","author":"Beer B","year":"2010","unstructured":"Beer B, Rabl W, Libiseller K, et al (2010) Impact of slow-release oral morphine on drug abusing habits in Austria. Neuropsychiatry 24(2): 108\u2013117.","journal-title":"Neuropsychiatry"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2025.1525510"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2010.03145.x"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0809890"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.8049"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19074106"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1037\/pha0000550"},{"issue":"12","key":"e_1_3_3_61_1","first-page":"542","article-title":"Reserpine and phencyclidine-associated psychosis: Three case reports","volume":"46","author":"Berlant JL","year":"1985","unstructured":"Berlant JL (1985) Reserpine and phencyclidine-associated psychosis: Three case reports. The Journal of Clinical Psychiatry 46(12): 542\u2013544.","journal-title":"The Journal of Clinical Psychiatry"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2010.02.006"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-023-10201-7"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-074668"},{"key":"e_1_3_3_65_1","unstructured":"Best Practice Advocacy Centre New Zealand (2021) Withdrawing patients from long-term use of benzodiazepines or zopiclone. Available at: https:\/\/bpac.org.nz\/2021\/benzo.aspx (accessed 17 December 2025)."},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00730-8"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.3109\/14659891.2015.1040092"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104287"},{"issue":"175","key":"e_1_3_3_69_1","first-page":"1","article-title":"A phase III multisite randomised controlled trial to compare the efficacy of cannabidiol to placebo in the treatment of cannabis use disorder: The CBD-CUD study protocol","volume":"24","author":"Bhardwaj AK","year":"2024","unstructured":"Bhardwaj AK, Mills L, Doyle M, et al (2024) A phase III multisite randomised controlled trial to compare the efficacy of cannabidiol to placebo in the treatment of cannabis use disorder: The CBD-CUD study protocol. BMC Psychiatry 24(175): 1\u201316.","journal-title":"BMC Psychiatry"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.57187\/s.4072"},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001185"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2018.02.023"},{"issue":"5","key":"e_1_3_3_73_1","first-page":"593","article-title":"A case of ketamine dependence","volume":"43","author":"B\u0142achut M","year":"2009","unstructured":"B\u0142achut M, \u0142 \u00f3 KS, Ruman J, et al (2009) A case of ketamine dependence. Psychiatria Polska 43(5): 593\u2013599","journal-title":"Psychiatria Polska"},{"key":"e_1_3_3_74_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.549272"},{"key":"e_1_3_3_75_1","unstructured":"BNF (2025) Gabapentin. Available at: https:\/\/bnf.nice.org.uk\/drugs\/gabapentin\/ (accessed 21 May 2025)."},{"key":"e_1_3_3_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109553"},{"key":"e_1_3_3_77_1","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.19r02513"},{"key":"e_1_3_3_78_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1465-3362.2011.00353.x"},{"key":"e_1_3_3_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2017.08.430"},{"key":"e_1_3_3_80_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.70013"},{"key":"e_1_3_3_81_1","doi-asserted-by":"publisher","DOI":"10.1111\/acem.14911"},{"key":"e_1_3_3_82_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001070"},{"key":"e_1_3_3_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2003.10.012"},{"key":"e_1_3_3_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102507"},{"key":"e_1_3_3_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(03)00071-1"},{"key":"e_1_3_3_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2018.04.023"},{"key":"e_1_3_3_87_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwu190"},{"key":"e_1_3_3_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2012.05.006"},{"key":"e_1_3_3_89_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.170958"},{"key":"e_1_3_3_90_1","first-page":"1","article-title":"Joint clinical practice guideline on benzodiazepine tapering: Considerations when risks outweigh benefits","volume":"2025","author":"Brunner E","year":"2025","unstructured":"Brunner E, Chen CYA, Klein T, et al (2025) Joint clinical practice guideline on benzodiazepine tapering: Considerations when risks outweigh benefits. Journal of General Internal Medicine 2025: 1\u201346.","journal-title":"Journal of General Internal Medicine"},{"key":"e_1_3_3_91_1","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12905"},{"key":"e_1_3_3_92_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.1999.94913114.x"},{"key":"e_1_3_3_93_1","doi-asserted-by":"publisher","DOI":"10.1037\/0021-843X.112.3.393"},{"key":"e_1_3_3_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2006.04.014"},{"key":"e_1_3_3_95_1","doi-asserted-by":"crossref","unstructured":"Buffel du Vaure C Dechartres A Battin C et al (2016) Exclusion of patients with concomitant chronic conditions in ongoing randomised controlled trials targeting 10 common chronic conditions and registered at ClinicalTrials.gov: A systematic review of registration details. BMJ Open 6(9): e012265.","DOI":"10.1136\/bmjopen-2016-012265"},{"key":"e_1_3_3_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2022.108832"},{"key":"e_1_3_3_97_1","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X13666141210215423"},{"key":"e_1_3_3_98_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD016058.pub2"},{"key":"e_1_3_3_99_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000162804.38829.97"},{"key":"e_1_3_3_100_1","doi-asserted-by":"publisher","DOI":"10.1111\/acer.13313"},{"key":"e_1_3_3_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0033-3182(83)73143-9"},{"key":"e_1_3_3_102_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012254.pub2"},{"key":"e_1_3_3_103_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007380.pub4"},{"key":"e_1_3_3_104_1","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0000000000001719"},{"key":"e_1_3_3_105_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.13975"},{"key":"e_1_3_3_106_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000684"},{"key":"e_1_3_3_107_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.12978"},{"key":"e_1_3_3_108_1","article-title":"Treatment interventions to maintain abstinence from alcohol in primary care: Systematic review and network meta-analysis","volume":"371","author":"Cheng HY","year":"2020","unstructured":"Cheng HY, McGuinness LA, Elbers RG, et al (2020) Treatment interventions to maintain abstinence from alcohol in primary care: Systematic review and network meta-analysis. BMJ 371: m3934.","journal-title":"BMJ"},{"key":"e_1_3_3_109_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2024.175"},{"key":"e_1_3_3_110_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(03)00058-9"},{"key":"e_1_3_3_111_1","doi-asserted-by":"publisher","DOI":"10.1177\/2049463720912496"},{"key":"e_1_3_3_112_1","doi-asserted-by":"publisher","DOI":"10.1097\/YCO.0000000000000717"},{"key":"e_1_3_3_113_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010078.pub3"},{"key":"e_1_3_3_114_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.12073"},{"key":"e_1_3_3_115_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2019.3655"},{"key":"e_1_3_3_116_1","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2011.124"},{"key":"e_1_3_3_117_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.15743"},{"issue":"52","key":"e_1_3_3_118_1","first-page":"3","article-title":"Adverse effects of synthetic cannabinoids: Management of acute toxicity and withdrawal","volume":"18","author":"Cooper ZD","year":"2016","unstructured":"Cooper ZD (2016) Adverse effects of synthetic cannabinoids: Management of acute toxicity and withdrawal. Current Psychiatry Reports 18(52): 3\u201310.","journal-title":"Current Psychiatry Reports"},{"key":"e_1_3_3_119_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1369-1600.2012.00461.x"},{"key":"e_1_3_3_120_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.14281"},{"key":"e_1_3_3_121_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2010.05.010"},{"key":"e_1_3_3_122_1","doi-asserted-by":"publisher","DOI":"10.1097\/CXA.0000000000000168"},{"key":"e_1_3_3_123_1","volume-title":"Statement on the potential toxicological risks from electronic nicotine (and non-nicotine) delivery systems (E(N)NDS-e-cigarettes)","author":"COT","year":"2020","unstructured":"COT (2020) Statement on the potential toxicological risks from electronic nicotine (and non-nicotine) delivery systems (E(N)NDS-e-cigarettes). Committee on toxicity of chemicals in food, consumer products and the environment. HM Government, UK."},{"key":"e_1_3_3_124_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.7621"},{"key":"e_1_3_3_125_1","doi-asserted-by":"publisher","DOI":"10.1101\/2024.08.12.24311617"},{"key":"e_1_3_3_126_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30866"},{"key":"e_1_3_3_127_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-021-05945-1"},{"key":"e_1_3_3_128_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104219"},{"key":"e_1_3_3_129_1","unstructured":"CRISM (2019) Injectable Opioid Agonist Treatment: iOAT for Opioid Use Disorder. Available at: https:\/\/crism.ca\/projects\/ioat-guideline\/(accessed 17 December 2025)."},{"key":"e_1_3_3_130_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2006.01494.x"},{"key":"e_1_3_3_131_1","doi-asserted-by":"publisher","DOI":"10.1093\/alcalc\/agad050"},{"key":"e_1_3_3_132_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.16600"},{"key":"e_1_3_3_133_1","volume-title":"StatPearls","author":"Danyalian A","year":"2023","unstructured":"Danyalian A, Heller D (2023) Central pontine myelinolysis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing."},{"key":"e_1_3_3_134_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.14729"},{"key":"e_1_3_3_135_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.16055"},{"key":"e_1_3_3_136_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009652.pub2"},{"key":"e_1_3_3_137_1","doi-asserted-by":"publisher","DOI":"10.1192\/apt.11.4.253"},{"key":"e_1_3_3_138_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2018.00708"},{"key":"e_1_3_3_139_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(15)00508-8"},{"key":"e_1_3_3_140_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(18)30337-7"},{"key":"e_1_3_3_141_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(23)00095-0"},{"key":"e_1_3_3_142_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2023.115318"},{"key":"e_1_3_3_143_1","doi-asserted-by":"publisher","DOI":"10.1080\/10550887.2021.1907502"},{"key":"e_1_3_3_144_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbae034"},{"key":"e_1_3_3_145_1","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.19.3.320"},{"key":"e_1_3_3_146_1","unstructured":"DHSC (2024) Oral methadone and buprenorphine: Recommendations. Available at: https:\/\/www.gov.uk\/government\/publications\/medicine-choices-in-opioid-substitution-treatment\/oral-methadone-and-buprenorphine-recommendations (accessed 21 October 2025)."},{"key":"e_1_3_3_147_1","unstructured":"DHSC (2025). Clinical guidelines for alcohol treatment.UK Department of Health and Social Care. https:\/\/www.gov.uk\/guidance\/clinical-guidelines-for-alcohol-treatment (accessed 16 December 2025)."},{"key":"e_1_3_3_148_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12245"},{"key":"e_1_3_3_149_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.330.7503.1297"},{"key":"e_1_3_3_150_1","doi-asserted-by":"publisher","DOI":"10.1111\/acer.14843"},{"issue":"3","key":"e_1_3_3_151_1","first-page":"230","article-title":"Treatment of phencyclidine-associated psychosis with ECT","volume":"4","author":"Dinwiddie SH","year":"1988","unstructured":"Dinwiddie SH, Drevets WC, Smith DR (1988) Treatment of phencyclidine-associated psychosis with ECT. Convulsive Therapy 4(3): 230\u2013235.","journal-title":"Convulsive Therapy"},{"key":"e_1_3_3_152_1","volume-title":"Drug misuse and dependence: UK clinical guidelines on clinical management","author":"DoH","year":"2017","unstructured":"DoH (2017) Drug misuse and dependence: UK clinical guidelines on clinical management. London: Department of Health."},{"key":"e_1_3_3_153_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881119889296"},{"key":"e_1_3_3_154_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(18)30427-9"},{"key":"e_1_3_3_155_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-023-01307-2"},{"key":"e_1_3_3_156_1","doi-asserted-by":"publisher","DOI":"10.1037\/amp0000744"},{"key":"e_1_3_3_157_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2011.03771.x"},{"key":"e_1_3_3_158_1","doi-asserted-by":"publisher","DOI":"10.1177\/07067437241262967"},{"key":"e_1_3_3_159_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2025.112789"},{"key":"e_1_3_3_160_1","unstructured":"EMA (2025) EMA to review sodium oxybate. Available at: https:\/\/www.ema.europa.eu\/en\/news\/ema-starts-review-sodium-oxybate-alcohol-dependence (accessed 25 July 2025)."},{"key":"e_1_3_3_161_1","author":"EMCDDA","year":"2018","unstructured":"EMCDDA (2018) Perspectives on drugs: The misuse of benzodiazepines among high-risk opioid users in Europe.","journal-title":"Perspectives on drugs: The misuse of benzodiazepines among high-risk opioid users in Europe"},{"key":"e_1_3_3_162_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(17)30075-5"},{"key":"e_1_3_3_163_1","doi-asserted-by":"publisher","DOI":"10.1177\/29767342241242242"},{"key":"e_1_3_3_164_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12186101"},{"key":"e_1_3_3_165_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.16730"},{"key":"e_1_3_3_166_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-019-1086-0"},{"key":"e_1_3_3_167_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002208"},{"key":"e_1_3_3_168_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000133"},{"key":"e_1_3_3_169_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-025-01153-8"},{"key":"e_1_3_3_170_1","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2006.100180"},{"key":"e_1_3_3_171_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881118817166"},{"key":"e_1_3_3_172_1","doi-asserted-by":"publisher","DOI":"10.1080\/10550887.2011.642758"},{"key":"e_1_3_3_173_1","doi-asserted-by":"publisher","DOI":"10.1080\/10550887.2013.824333"},{"key":"e_1_3_3_174_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32230-5"},{"key":"e_1_3_3_175_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2024.104390"},{"key":"e_1_3_3_176_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-895X(25)09174-6"},{"key":"e_1_3_3_177_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000084032.22282.ff"},{"key":"e_1_3_3_178_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003410.pub4"},{"key":"e_1_3_3_179_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph17091125"},{"key":"e_1_3_3_180_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03405469"},{"key":"e_1_3_3_181_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2006.01321.x"},{"key":"e_1_3_3_182_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-023-03523-2"},{"key":"e_1_3_3_183_1","doi-asserted-by":"publisher","DOI":"10.5055\/jom.2022.0752"},{"key":"e_1_3_3_184_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.16680"},{"key":"e_1_3_3_185_1","doi-asserted-by":"publisher","DOI":"10.1111\/1467-9566.13180"},{"key":"e_1_3_3_186_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(20)30290-X"},{"key":"e_1_3_3_187_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.15253"},{"key":"e_1_3_3_188_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(84)90030-8"},{"key":"e_1_3_3_189_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0740-5472(96)00154-7"},{"key":"e_1_3_3_190_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14432"},{"key":"e_1_3_3_191_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.110958"},{"key":"e_1_3_3_192_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2014.04.004"},{"key":"e_1_3_3_193_1","doi-asserted-by":"publisher","DOI":"10.1093\/alcalc\/agaa125"},{"key":"e_1_3_3_194_1","doi-asserted-by":"publisher","DOI":"10.1097\/CXA.0000000000000072"},{"issue":"6","key":"e_1_3_3_195_1","first-page":"493","article-title":"Space-based abstinence: Alleviation of withdrawal symptoms in combinative cocaine-phencyclidine abuse","volume":"25","author":"Giannini AJ","year":"1987","unstructured":"Giannini AJ, Loiselle RH (1987) Space-based abstinence: Alleviation of withdrawal symptoms in combinative cocaine-phencyclidine abuse. Clinical Toxicology 25(6): 493\u2013500.","journal-title":"Clinical Toxicology"},{"key":"e_1_3_3_196_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1986.tb02936.x"},{"key":"e_1_3_3_197_1","doi-asserted-by":"publisher","DOI":"10.1016\/0740-5472(93)90055-7"},{"key":"e_1_3_3_198_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-020-05476-1"},{"key":"e_1_3_3_199_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2016.02.028"},{"key":"e_1_3_3_200_1","doi-asserted-by":"publisher","DOI":"10.1080\/13556210500123126"},{"key":"e_1_3_3_201_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002396"},{"key":"e_1_3_3_202_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116636545"},{"key":"e_1_3_3_203_1","doi-asserted-by":"publisher","DOI":"10.1080\/09540120220097955"},{"key":"e_1_3_3_204_1","doi-asserted-by":"publisher","DOI":"10.1111\/ACEM.15093"},{"key":"e_1_3_3_205_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.113.126003"},{"key":"e_1_3_3_206_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002022.pub3"},{"key":"e_1_3_3_207_1","unstructured":"Gowing L Ali R Farrell M et al (2014) National guidelines for medication-assisted treatment of opioid dependence. Available at: https:\/\/www.health.gov.au\/resources\/publications\/national-guidelines-for-medication-assisted-treatment-of-opioid-dependence?language=en (accessed 3 October 2025)."},{"key":"e_1_3_3_208_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002024.pub5"},{"key":"e_1_3_3_209_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002025.pub5"},{"key":"e_1_3_3_210_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.110891"},{"key":"e_1_3_3_211_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2012.12010055"},{"key":"e_1_3_3_212_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-025-02061-y"},{"key":"e_1_3_3_213_1","doi-asserted-by":"publisher","DOI":"10.2147\/SAR.S431270"},{"key":"e_1_3_3_214_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psc.2010.01.004"},{"key":"e_1_3_3_215_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-023-00906-7"},{"key":"e_1_3_3_216_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2023.115626"},{"key":"e_1_3_3_217_1","doi-asserted-by":"publisher","DOI":"10.1093\/alcalc\/36.5.413"},{"key":"e_1_3_3_218_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-012-0061-5"},{"key":"e_1_3_3_219_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20251002"},{"key":"e_1_3_3_220_1","doi-asserted-by":"publisher","DOI":"10.1093\/alcalc\/agac070"},{"key":"e_1_3_3_221_1","doi-asserted-by":"publisher","DOI":"10.4103\/psychiatry.IndianJPsychiatry_40_17"},{"key":"e_1_3_3_222_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-013-0292-0"},{"key":"e_1_3_3_223_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.106.026112"},{"key":"e_1_3_3_224_1","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.51254"},{"key":"e_1_3_3_225_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01808-0"},{"key":"e_1_3_3_226_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000031.pub6"},{"key":"e_1_3_3_227_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2014.05.012"},{"key":"e_1_3_3_228_1","doi-asserted-by":"publisher","DOI":"10.2147\/SAR.S109919"},{"key":"e_1_3_3_229_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-015-0240-4"},{"key":"e_1_3_3_230_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2021.1271"},{"key":"e_1_3_3_231_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.13670"},{"key":"e_1_3_3_232_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300310"},{"key":"e_1_3_3_233_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-007-1020-8"},{"key":"e_1_3_3_234_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-010-1888-6"},{"key":"e_1_3_3_235_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2013.54"},{"key":"e_1_3_3_236_1","doi-asserted-by":"publisher","DOI":"10.1111\/adb.12621"},{"key":"e_1_3_3_237_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2013.12060782"},{"key":"e_1_3_3_238_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.12581"},{"key":"e_1_3_3_239_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2025.100329"},{"key":"e_1_3_3_240_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7350.1350"},{"key":"e_1_3_3_241_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2024.1322434"},{"key":"e_1_3_3_242_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(75)90152-5"},{"key":"e_1_3_3_243_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(25)30227-2"},{"key":"e_1_3_3_244_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI172889"},{"key":"e_1_3_3_245_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11481-019-09883-w"},{"key":"e_1_3_3_246_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.15329"},{"key":"e_1_3_3_247_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.17128"},{"key":"e_1_3_3_248_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-016-4298-6"},{"key":"e_1_3_3_249_1","doi-asserted-by":"publisher","DOI":"10.1111\/adb.12664"},{"key":"e_1_3_3_250_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1521-0391.2011.00159.x"},{"key":"e_1_3_3_251_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-024-06191-3"},{"key":"e_1_3_3_252_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.14188"},{"key":"e_1_3_3_253_1","doi-asserted-by":"publisher","DOI":"10.12793\/tcp.2018.26.2.56"},{"key":"e_1_3_3_254_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-019-04899-7"},{"key":"e_1_3_3_255_1","volume-title":"The Maudsley Deprescribing Guidelines: Antidepressants, Benzodiazepines, Gabapentinoids and Z-Drugs","author":"Horowitz M","year":"2024","unstructured":"Horowitz M, Taylor D (2024) The Maudsley Deprescribing Guidelines: Antidepressants, Benzodiazepines, Gabapentinoids and Z-Drugs. Wiley Blackwell."},{"key":"e_1_3_3_256_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.54.2.161"},{"key":"e_1_3_3_257_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.12333"},{"key":"e_1_3_3_258_1","doi-asserted-by":"publisher","DOI":"10.2147\/SAR.S375653"},{"key":"e_1_3_3_259_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291721002051"},{"key":"e_1_3_3_260_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2015.11.011"},{"key":"e_1_3_3_261_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.13518"},{"key":"e_1_3_3_262_1","doi-asserted-by":"publisher","DOI":"10.1093\/ntr\/ntq009"},{"key":"e_1_3_3_263_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn8238"},{"key":"e_1_3_3_264_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13326"},{"key":"e_1_3_3_265_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.54962"},{"key":"e_1_3_3_266_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2004.11.013"},{"key":"e_1_3_3_267_1","doi-asserted-by":"publisher","DOI":"10.1080\/10550490802266276"},{"key":"e_1_3_3_268_1","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002572"},{"key":"e_1_3_3_269_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11011-013-9457-4"},{"key":"e_1_3_3_270_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12070"},{"key":"e_1_3_3_271_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145713001557"},{"key":"e_1_3_3_272_1","first-page":"388","article-title":"Management of alcohol withdrawal syndromes in general hospital settings","author":"Kast KA","year":"2025","unstructured":"Kast KA, Sidelnik SA, Nejad SH, et al (2025) Management of alcohol withdrawal syndromes in general hospital settings. BMJ 388.","journal-title":"BMJ"},{"key":"e_1_3_3_273_1","doi-asserted-by":"publisher","DOI":"10.1093\/alcalc\/agaa050"},{"key":"e_1_3_3_274_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-020-06448-z"},{"key":"e_1_3_3_275_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2008.02248.x"},{"key":"e_1_3_3_276_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001207"},{"key":"e_1_3_3_277_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2022.107570"},{"key":"e_1_3_3_278_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2010.06.002"},{"key":"e_1_3_3_279_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12873-021-00524-1"},{"key":"e_1_3_3_280_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2009.11.006"},{"key":"e_1_3_3_281_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.12369"},{"key":"e_1_3_3_282_1","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0b013e31828bfb6e"},{"key":"e_1_3_3_283_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.12862"},{"key":"e_1_3_3_284_1","doi-asserted-by":"publisher","DOI":"10.1002\/npr2.12232"},{"key":"e_1_3_3_285_1","doi-asserted-by":"publisher","DOI":"10.1111\/acer.15118"},{"key":"e_1_3_3_286_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181ac5213"},{"key":"e_1_3_3_287_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-019-0536-z"},{"key":"e_1_3_3_288_1","doi-asserted-by":"publisher","DOI":"10.1016\/0740-5472(92)90081-X"},{"key":"e_1_3_3_289_1","doi-asserted-by":"publisher","DOI":"10.1037\/neu0000615"},{"key":"e_1_3_3_290_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cger.2014.04.008"},{"key":"e_1_3_3_291_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2022.117"},{"key":"e_1_3_3_292_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.16178"},{"key":"e_1_3_3_293_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2018.3537"},{"key":"e_1_3_3_294_1","doi-asserted-by":"publisher","DOI":"10.1080\/13556219772732"},{"key":"e_1_3_3_295_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.16154"},{"key":"e_1_3_3_296_1","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pnaa089"},{"key":"e_1_3_3_297_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2024.1456148"},{"key":"e_1_3_3_298_1","doi-asserted-by":"publisher","DOI":"10.1080\/00952990.2023.2175323"},{"key":"e_1_3_3_299_1","doi-asserted-by":"publisher","DOI":"10.1111\/acem.14825"},{"key":"e_1_3_3_300_1","doi-asserted-by":"publisher","DOI":"10.1080\/00952990.2024.2353649"},{"key":"e_1_3_3_301_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505409"},{"key":"e_1_3_3_302_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32812-X"},{"key":"e_1_3_3_303_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-013-0137-z"},{"key":"e_1_3_3_304_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2015.15040567"},{"key":"e_1_3_3_305_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2015.04.008"},{"key":"e_1_3_3_306_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32531"},{"key":"e_1_3_3_307_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108350"},{"key":"e_1_3_3_308_1","doi-asserted-by":"publisher","DOI":"10.1093\/alcalc\/33.6.563"},{"issue":"2","key":"e_1_3_3_309_1","first-page":"105","article-title":"A protocol to switch high-dose, methadone-maintained subjects to buprenorphine","volume":"6","author":"Levin FR","year":"1997","unstructured":"Levin FR, Fischman MW, Connerney I, et al (1997) A protocol to switch high-dose, methadone-maintained subjects to buprenorphine. The American Journal on Addictions 6(2): 105\u2013116.","journal-title":"The American Journal on Addictions"},{"key":"e_1_3_3_310_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2010.12.010"},{"key":"e_1_3_3_311_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.12108"},{"key":"e_1_3_3_312_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2015.11.025"},{"key":"e_1_3_3_313_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.16093"},{"issue":"1","key":"e_1_3_3_314_1","first-page":"31","article-title":"Ketamine associated psychedelic effects and dependence","volume":"44","author":"Lim DK","year":"2003","unstructured":"Lim DK (2003) Ketamine associated psychedelic effects and dependence. Singapore Medical Journal 44(1): 31\u201334.","journal-title":"Singapore Medical Journal"},{"key":"e_1_3_3_315_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31816727e2"},{"key":"e_1_3_3_316_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015226.pub2"},{"key":"e_1_3_3_317_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010216.pub9"},{"key":"e_1_3_3_318_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.1427"},{"key":"e_1_3_3_319_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2011.03619.x"},{"key":"e_1_3_3_320_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000647"},{"key":"e_1_3_3_321_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2019.11.004"},{"key":"e_1_3_3_322_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881112444324"},{"key":"e_1_3_3_323_1","volume-title":"Clinical guidelines for use of depot buprenorphine (Buvidal\u00ae and Sublocade\u00ae) in the treatment of opioid dependence","author":"Lintzeris N","year":"2019","unstructured":"Lintzeris N, Dunlop A, Masters d (2019) Clinical guidelines for use of depot buprenorphine (Buvidal\u00ae and Sublocade\u00ae) in the treatment of opioid dependence. New South Wales: Ministry of Health."},{"key":"e_1_3_3_324_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2019.1993"},{"key":"e_1_3_3_325_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000855"},{"key":"e_1_3_3_326_1","unstructured":"Lintzeris N Dunlop A Schulz M (2024) Long-acting injectable buprenorphine (LAIB) for opioid dependence treatment: Practice Guide. Available at: https:\/\/www.health.nsw.gov.au\/aod\/resources\/Pages\/laib.aspx (accessed 29 August 2025)."},{"key":"e_1_3_3_327_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008502.pub6"},{"key":"e_1_3_3_328_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006103.pub8"},{"key":"e_1_3_3_329_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015314.pub2"},{"key":"e_1_3_3_330_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11051154"},{"key":"e_1_3_3_331_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.13843"},{"key":"e_1_3_3_332_1","doi-asserted-by":"publisher","DOI":"10.1111\/dar.12225"},{"issue":"1","key":"e_1_3_3_333_1","first-page":"1","article-title":"Hazardous drinking and alcohol use disorders","volume":"8","author":"MacKillop J","year":"2022","unstructured":"MacKillop J, Agabio R, Feldstein Ewing SW, et al (2022) Hazardous drinking and alcohol use disorders. Nature Reviews Disease Primers 2022 8:1 8(1): 1\u201325.","journal-title":"Nature Reviews Disease Primers 2022 8:1"},{"key":"e_1_3_3_334_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002965"},{"key":"e_1_3_3_335_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-10970-x"},{"key":"e_1_3_3_336_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2012.04054.x"},{"key":"e_1_3_3_337_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2025.1216"},{"key":"e_1_3_3_338_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1392027"},{"key":"e_1_3_3_339_1","doi-asserted-by":"publisher","DOI":"10.1111\/adb.12012"},{"key":"e_1_3_3_340_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2016.10.008"},{"key":"e_1_3_3_341_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2021.1916470"},{"key":"e_1_3_3_342_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-023-04927-1"},{"key":"e_1_3_3_343_1","doi-asserted-by":"publisher","DOI":"10.1080\/10550490701525467"},{"key":"e_1_3_3_344_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.13193"},{"key":"e_1_3_3_345_1","first-page":"66","article-title":"Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: A pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial","author":"Marsden J","year":"2023","unstructured":"Marsden J, Kelleher M, Gilvarry E, et al (2023) Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: A pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial. eClinicalMedicine 66.","journal-title":"eClinicalMedicine"},{"key":"e_1_3_3_346_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00529"},{"key":"e_1_3_3_347_1","unstructured":"Mason B (2017) Gabapentin Treatment of Cannabis Dependence (NCT00974376). Available at: https:\/\/clinicaltrials.gov\/study\/NCT00974376 (accessed 31 August 2025)."},{"key":"e_1_3_3_348_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2012.14"},{"key":"e_1_3_3_349_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2013.11950"},{"key":"e_1_3_3_350_1","doi-asserted-by":"publisher","DOI":"10.1093\/alcalc\/agx090"},{"key":"e_1_3_3_351_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy12050152"},{"key":"e_1_3_3_352_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002207.pub4"},{"key":"e_1_3_3_353_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002209.pub2"},{"key":"e_1_3_3_354_1","first-page":"241","article-title":"Gabapentin to treat acute alcohol withdrawal in hospitalized patients: A systematic review and meta-analysis","author":"Mattle AG","year":"2022","unstructured":"Mattle AG, McGrath P, Sanu A, et al (2022) Gabapentin to treat acute alcohol withdrawal in hospitalized patients: A systematic review and meta-analysis. Drug and Alcohol Dependence 241.","journal-title":"Drug and Alcohol Dependence"},{"key":"e_1_3_3_355_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201800321"},{"key":"e_1_3_3_356_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-013-1127-0"},{"key":"e_1_3_3_357_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1465-3362.2010.00237.x"},{"key":"e_1_3_3_358_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03550020076042"},{"key":"e_1_3_3_359_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.13.1405"},{"key":"e_1_3_3_360_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881117699361"},{"key":"e_1_3_3_361_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104236"},{"key":"e_1_3_3_362_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000099"},{"key":"e_1_3_3_363_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20230508"},{"key":"e_1_3_3_364_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.13326"},{"key":"e_1_3_3_365_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2005.01160.x"},{"key":"e_1_3_3_366_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1129447"},{"key":"e_1_3_3_367_1","article-title":"Consideration of sex and gender differences in addiction medication response","author":"McKee SA","year":"2022","unstructured":"McKee SA, McRae-Clark AL (2022) Consideration of sex and gender differences in addiction medication response. Biology of Sex Differences.","journal-title":"Biology of Sex Differences"},{"key":"e_1_3_3_368_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2019.09.014"},{"key":"e_1_3_3_369_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101005"},{"key":"e_1_3_3_370_1","volume-title":"Nicotine vaping in England: An evidence update including health risks and perceptions, 2022","author":"McNeill A","year":"2022","unstructured":"McNeill A, Simonavi\u010dius E, Brose L, et al (2022) Nicotine vaping in England: An evidence update including health risks and perceptions, 2022. London: Office for Health Improvement and Disparities (OHID)."},{"key":"e_1_3_3_371_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19761"},{"key":"e_1_3_3_372_1","unstructured":"McRae-Clark (2024) UH3 varenicline for cannabis use disorder. Available at: https:\/\/www.clinicaltrials.gov\/study\/NCT03980561 (accessed 6 July 2025)."},{"key":"e_1_3_3_373_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.109111"},{"key":"e_1_3_3_374_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2009.06.022"},{"key":"e_1_3_3_375_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2009.12.008"},{"key":"e_1_3_3_376_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.1985.tb05290.x"},{"key":"e_1_3_3_377_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.15357"},{"key":"e_1_3_3_378_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.adt.0000186359.43340.76"},{"key":"e_1_3_3_379_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001333.pub4"},{"key":"e_1_3_3_380_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006754.pub4"},{"key":"e_1_3_3_381_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006318.pub4"},{"key":"e_1_3_3_382_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015673.pub2"},{"key":"e_1_3_3_383_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2004.00764.x"},{"key":"e_1_3_3_384_1","doi-asserted-by":"publisher","DOI":"10.1080\/14659891.2024.2342313"},{"key":"e_1_3_3_385_1","doi-asserted-by":"publisher","DOI":"10.1080\/00952990.2021.1887202"},{"key":"e_1_3_3_386_1","doi-asserted-by":"publisher","DOI":"10.1017\/cem.2019.471"},{"key":"e_1_3_3_387_1","first-page":"114","article-title":"Short communication: Systematic review on effectiveness of micro-induction approaches to buprenorphine initiation","author":"Moe J","year":"2021","unstructured":"Moe J, O\u2019Sullivan F, Hohl CM, et al (2021) Short communication: Systematic review on effectiveness of micro-induction approaches to buprenorphine initiation. Addictive Behaviors 114.","journal-title":"Addictive Behaviors"},{"key":"e_1_3_3_388_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-007-0129-0"},{"key":"e_1_3_3_389_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000200"},{"key":"e_1_3_3_390_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.107994"},{"issue":"181","key":"e_1_3_3_391_1","first-page":"1","article-title":"Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function","volume":"8","author":"Morgan CJA","year":"2018","unstructured":"Morgan CJA, Freeman TP, Hindocha C, et al (2018) Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function. Translational Psychiatry 8(181): 1\u201310.","journal-title":"Translational Psychiatry"},{"key":"e_1_3_3_392_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-025-01225-0"},{"key":"e_1_3_3_393_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0256752"},{"key":"e_1_3_3_394_1","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0000000000000913"},{"key":"e_1_3_3_395_1","unstructured":"Mylan (2022) Librium 5 mg Capsules \u2013 Summary of Product Characteristics (SmPC). Available at: https:\/\/www.medicines.org.uk\/emc\/product\/1728\/smpc (accessed 2 September 2025)."},{"key":"e_1_3_3_396_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1282831"},{"key":"e_1_3_3_397_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.121.000442"},{"key":"e_1_3_3_398_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109295"},{"key":"e_1_3_3_399_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-018-0544-4"},{"key":"e_1_3_3_400_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2024.108118"},{"key":"e_1_3_3_401_1","unstructured":"NICE (2007) TA114: Methadone and buprenorphine for the management of opioid dependence. Available at: www.nice.org.uk\/guidance\/ta114 (accessed 10 September 2025)."},{"key":"e_1_3_3_402_1","unstructured":"NICE (2010) CG100: Alcohol-use disorders: Diagnosis and management of physical complications. Available at: www.nice.org.uk\/guidance\/cg100 (accessed 15 April 2025)."},{"key":"e_1_3_3_403_1","unstructured":"NICE (2019) ES19: Opioid dependence: Buprenorphine prolonged-release injection (Buvidal). Available at: www.nice.org.uk\/guidance\/es19 (accessed 15 September 2025)."},{"key":"e_1_3_3_404_1","unstructured":"NICE (2021) NG193: Chronic pain (primary and secondary) in over 16s: Assessment of all chronic pain and management of chronic primary pain. Available at: www.nice.org.uk\/guidance\/ng193 (accessed 12 October 2025)."},{"key":"e_1_3_3_405_1","unstructured":"NICE (2022) NG215: Medicines associated with dependence or withdrawal symptoms: Safe prescribing and withdrawal management for adults. Available at: www.nice.org.uk\/guidance\/ng215 (accessed 3 October 2025)."},{"key":"e_1_3_3_406_1","unstructured":"NICE (2024) Benzodiazepine and Z-drug withdrawal: Clinical Knowledge Summary. Available at: https:\/\/cks.nice.org.uk\/topics\/benzodiazepine-z-drug-withdrawal\/ (accessed 8 July 2025)."},{"key":"e_1_3_3_407_1","unstructured":"NICE (2025) NG209: Tobacco: Preventing uptake promoting quitting and treating dependence. Available at: www.nice.org.uk\/guidance\/ng209 (accessed 8 October 2025)."},{"key":"e_1_3_3_408_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07804-3"},{"key":"e_1_3_3_409_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0b013e318277e92e"},{"key":"e_1_3_3_410_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2014.06.006"},{"key":"e_1_3_3_411_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011117.pub3"},{"key":"e_1_3_3_412_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108519"},{"key":"e_1_3_3_413_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.110669"},{"key":"e_1_3_3_414_1","volume-title":"Management of Withdrawal from Alcohol and Other Drugs: Clinical Guidance","author":"NSW Ministry of Health","year":"2022","unstructured":"NSW Ministry of Health (2022) Management of Withdrawal from Alcohol and Other Drugs: Clinical Guidance. NSW Ministry of Health."},{"key":"e_1_3_3_415_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61462-6"},{"key":"e_1_3_3_416_1","doi-asserted-by":"publisher","DOI":"10.1111\/dar.13228"},{"key":"e_1_3_3_417_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.156973"},{"key":"e_1_3_3_418_1","unstructured":"ONS (2024) Deaths related to drug poisoning in England and Wales. Available at: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/deaths\/bulletins\/deathsrelatedtodrugpoisoninginenglandandwales\/2023registrations (accessed 12 August 2025)."},{"key":"e_1_3_3_419_1","doi-asserted-by":"publisher","DOI":"10.1080\/08964289.2020.1760777"},{"key":"e_1_3_3_420_1","doi-asserted-by":"publisher","DOI":"10.3390\/pathophysiology30010004"},{"key":"e_1_3_3_421_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2015.05.004"},{"key":"e_1_3_3_422_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1465-3362.2009.00100.x"},{"key":"e_1_3_3_423_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12012-019-09522-z"},{"key":"e_1_3_3_424_1","unstructured":"Pace C (2025) Alcohol withdrawal: Epidemiology clinical manifestations course assessment and diagnosis . Available at:https:\/\/www.uptodate.com\/contents\/alcohol-withdrawal-epidemiology-clinical-manifestations-course-assessment-and-diagnosis(accessed 21 July 2025)."},{"key":"e_1_3_3_425_1","doi-asserted-by":"publisher","DOI":"10.1177\/0310057X0203000323"},{"key":"e_1_3_3_426_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.3.533"},{"key":"e_1_3_3_427_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008373.pub2"},{"key":"e_1_3_3_428_1","first-page":"131","article-title":"\u201cIt could potentially be dangerous. but nothing else has seemed to help me.\u201d: Patient and clinician perspectives on benzodiazepine use in opioid agonist treatment","author":"Park TW","year":"2021","unstructured":"Park TW, Sikov J, dellaBitta V, et al (2021) \u201cIt could potentially be dangerous. but nothing else has seemed to help me.\u201d: Patient and clinician perspectives on benzodiazepine use in opioid agonist treatment. Journal of Substance Abuse Treatment 131.","journal-title":"Journal of Substance Abuse Treatment"},{"key":"e_1_3_3_429_1","doi-asserted-by":"publisher","DOI":"10.1002\/psb.1664"},{"key":"e_1_3_3_430_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2020.0246"},{"key":"e_1_3_3_431_1","article-title":"Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: Population based retrospective cohort study","volume":"368","author":"Pearce LA","year":"2020","unstructured":"Pearce LA, Min JE, Piske M, et al (2020) Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: Population based retrospective cohort study. BMJ 368: m772.","journal-title":"BMJ"},{"key":"e_1_3_3_432_1","doi-asserted-by":"publisher","DOI":"10.1080\/00952990.2021.1889575"},{"key":"e_1_3_3_433_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-9338(15)30856-7"},{"key":"e_1_3_3_434_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2006.03.074"},{"key":"e_1_3_3_435_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(22)00161-4"},{"key":"e_1_3_3_436_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2009.08060852"},{"key":"e_1_3_3_437_1","doi-asserted-by":"publisher","DOI":"10.1159\/000346179"},{"key":"e_1_3_3_438_1","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12210"},{"key":"e_1_3_3_439_1","unstructured":"PHE (2014) Advice for prescribers on the risk of the misuse of pregabalin and gabapentin. Available at: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/385791\/PHE-NHS_England_pregabalin_and_gabapentin_advice_Dec_2014.pdf (accessed 8 May 2025)."},{"key":"e_1_3_3_440_1","unstructured":"PHE (2021) Opioid substitution treatment: Guide for keyworkers. Available at: https:\/\/www.gov.uk\/government\/publications\/opioid-substitution-treatment-guide-for-keyworkers (accessed 3 October 2025)."},{"key":"e_1_3_3_441_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2018.02.005"},{"key":"e_1_3_3_442_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-024-04483-6"},{"key":"e_1_3_3_443_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n1011"},{"key":"e_1_3_3_444_1","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.12495"},{"key":"e_1_3_3_445_1","doi-asserted-by":"publisher","DOI":"10.1177\/10600280221130458"},{"issue":"5","key":"e_1_3_3_446_1","first-page":"339","article-title":"Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline","volume":"64","author":"Pottie K","year":"2018","unstructured":"Pottie K, Thompson W, Davies S, et al (2018) Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline. Canadian Family Physician 64(5): 339\u2013351.","journal-title":"Canadian Family Physician"},{"key":"e_1_3_3_447_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2025.112698"},{"key":"e_1_3_3_448_1","doi-asserted-by":"publisher","DOI":"10.1037\/0022-006X.72.6.1144"},{"key":"e_1_3_3_449_1","doi-asserted-by":"publisher","DOI":"10.1093\/fampra\/cmab073"},{"key":"e_1_3_3_450_1","doi-asserted-by":"publisher","DOI":"10.1177\/02698811241294005"},{"key":"e_1_3_3_451_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2024.2422964"},{"issue":"12","key":"e_1_3_3_452_1","first-page":"692","article-title":"Atomoxetine efficacy in methamphetamine dependence during methadone maintenance therapy","volume":"22","author":"Rabiey A","year":"2019","unstructured":"Rabiey A, Hassani-Abharian P, Farhad M, et al (2019) Atomoxetine efficacy in methamphetamine dependence during methadone maintenance therapy. Archives of Iranian Medicine 22(12): 692\u2013698.","journal-title":"Archives of Iranian Medicine"},{"key":"e_1_3_3_453_1","doi-asserted-by":"publisher","DOI":"10.1177\/02698811221142575"},{"key":"e_1_3_3_454_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14727"},{"key":"e_1_3_3_455_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.70034"},{"key":"e_1_3_3_456_1","doi-asserted-by":"publisher","DOI":"10.1177\/104012371502700410"},{"key":"e_1_3_3_457_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2020.20070993"},{"key":"e_1_3_3_458_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.8279"},{"key":"e_1_3_3_459_1","author":"RCP","year":"2024","unstructured":"RCP (2024) E-cigarettes and harm reduction: An evidence review. April.","journal-title":"E-cigarettes and harm reduction: An evidence review"},{"key":"e_1_3_3_460_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-017-2257-8"},{"key":"e_1_3_3_461_1","doi-asserted-by":"publisher","DOI":"10.1093\/alcalc\/agt021"},{"key":"e_1_3_3_462_1","doi-asserted-by":"publisher","DOI":"10.1093\/ntr\/ntr220"},{"key":"e_1_3_3_463_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2017.1750101"},{"key":"e_1_3_3_464_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000738"},{"key":"e_1_3_3_465_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001340"},{"key":"e_1_3_3_466_1","doi-asserted-by":"publisher","DOI":"10.1111\/ADD.70215"},{"key":"e_1_3_3_467_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109376"},{"key":"e_1_3_3_468_1","doi-asserted-by":"publisher","DOI":"10.1111\/dar.13979"},{"key":"e_1_3_3_469_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.13414"},{"key":"e_1_3_3_470_1","doi-asserted-by":"publisher","DOI":"10.1177\/02698811231158232"},{"key":"e_1_3_3_471_1","doi-asserted-by":"publisher","DOI":"10.1093\/alcalc\/agab057"},{"key":"e_1_3_3_472_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2018.00367"},{"issue":"5","key":"e_1_3_3_473_1","first-page":"220","article-title":"The efficacy of ECT in phencyclidine-induced psychosis","volume":"45","author":"Rosen AM","year":"1984","unstructured":"Rosen AM, Mukherjee S, Shinbach K (1984) The efficacy of ECT in phencyclidine-induced psychosis. Journal of Clinical Psychiatry 45(5): 220\u2013222.","journal-title":"Journal of Clinical Psychiatry"},{"key":"e_1_3_3_474_1","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0b013e318298ddad"},{"key":"e_1_3_3_475_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.12315"},{"key":"e_1_3_3_476_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.9382"},{"key":"e_1_3_3_477_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004332.pub2"},{"key":"e_1_3_3_478_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2020.20101480"},{"key":"e_1_3_3_479_1","author":"Royal College of Psychiatrists","year":"2025","unstructured":"Royal College of Psychiatrists (2025) College Report CR243: Co-occurring substance use and mental health disorders (CoSUM).","journal-title":"College Report CR243: Co-occurring substance use and mental health disorders (CoSUM)"},{"key":"e_1_3_3_480_1","unstructured":"RCPsych & BAP (2025). Gabapentinoids in psychiatric practice: Balancing the risks and benefits. Position Statement PS03\/25. https:\/\/www.bap.org.uk\/pdfs\/PS03_25_Gabapentinoids_in_psychiatric_practice.pdf (accessed 16 December 2025)."},{"key":"e_1_3_3_481_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00279-5"},{"key":"e_1_3_3_482_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-024-01355-6"},{"key":"e_1_3_3_483_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31822bb378"},{"key":"e_1_3_3_484_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000408"},{"key":"e_1_3_3_485_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-024-06696-5"},{"key":"e_1_3_3_486_1","unstructured":"SAMHSA (2021) TIP63 \u2013 Medications for opioid use disorder. Available at: https:\/\/library.samhsa.gov\/product\/tip-63-medications-opioid-use-disorder\/pep21-02-01-002 (accessed 16 December 2025)."},{"key":"e_1_3_3_487_1","unstructured":"SAMHSA (2024) Federal Guidelines for Opioid Treatment Programs. Available at: https:\/\/www.med.unc.edu\/fammed\/nctac\/wp-content\/uploads\/sites\/1256\/2025\/01\/federal-guidelines-opioid-treatment-pep24-02-011-1.pdf (accessed 20 September 2025)."},{"key":"e_1_3_3_488_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16075"},{"key":"e_1_3_3_489_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2021.0976"},{"key":"e_1_3_3_490_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20220335"},{"key":"e_1_3_3_491_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008358.pub2"},{"key":"e_1_3_3_492_1","doi-asserted-by":"publisher","DOI":"10.4103\/0972-6748.119652"},{"key":"e_1_3_3_493_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011983.pub2"},{"key":"e_1_3_3_494_1","doi-asserted-by":"publisher","DOI":"10.1097\/YCO.0000000000000332"},{"key":"e_1_3_3_495_1","unstructured":"SCENIHR (2008) Health Effects of Smokeless Tobacco Products. Available at: https:\/\/ec.europa.eu\/health\/ph_risk\/committee (accessed 16 December 2025)."},{"key":"e_1_3_3_496_1","doi-asserted-by":"publisher","DOI":"10.1037\/pha0000761"},{"key":"e_1_3_3_497_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyz007"},{"key":"e_1_3_3_498_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2018.01.017"},{"key":"e_1_3_3_499_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1407298"},{"key":"e_1_3_3_500_1","doi-asserted-by":"publisher","DOI":"10.2147\/SAR.S337338"},{"key":"e_1_3_3_501_1","unstructured":"Scottish Drug Deaths Taskforce (2024) MAT standards informed response for benzodiazepine harm reduction call to action. Available at: www.gov.uk\/drug-safety-update\/benzodiazepines-and-opioids-reminder-of-risk-of-potentially-fatal- (accessed 5 August 2025)."},{"key":"e_1_3_3_502_1","unstructured":"Scottish Government (2024) Quality Prescribing for Benzodiazepines and z-drugs: Guide for Improvement 2024 to 2027. Available at: https:\/\/www.gov.scot\/publications\/quality-prescribing-benzodiazepines-z-drugs-guide-improvement-2024-2027\/pages\/1\/ (accessed 17 December 2025)."},{"key":"e_1_3_3_503_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1205285"},{"key":"e_1_3_3_504_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2018.1427101"},{"key":"e_1_3_3_505_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2020.101301"},{"key":"e_1_3_3_506_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.16347"},{"key":"e_1_3_3_507_1","first-page":"1","article-title":"Synthetic cannabinoid withdrawal: A systematic review of case reports","author":"Sharma R","year":"2025","unstructured":"Sharma R, Weinstein A (2025) Synthetic cannabinoid withdrawal: A systematic review of case reports. European Addiction Research: 1\u201317.","journal-title":"European Addiction Research"},{"issue":"6","key":"e_1_3_3_508_1","article-title":"Detoxification: The use of benzodiazepines","volume":"30","author":"Shaw G","year":"1995","unstructured":"Shaw G (1995) Detoxification: The use of benzodiazepines. Alcohol and Alcoholism 30(6): 765\u201370.","journal-title":"Alcohol and Alcoholism"},{"key":"e_1_3_3_509_1","doi-asserted-by":"publisher","DOI":"10.1186\/1747-597X-4-1"},{"key":"e_1_3_3_510_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.318.7183.593"},{"key":"e_1_3_3_511_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(25)00174-4"},{"key":"e_1_3_3_512_1","doi-asserted-by":"publisher","DOI":"10.4212\/cjhp.v65i5.1176"},{"key":"e_1_3_3_513_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2020.20050610"},{"key":"e_1_3_3_514_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2006.03.005"},{"key":"e_1_3_3_515_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.9744"},{"key":"e_1_3_3_516_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-022-06283-6"},{"key":"e_1_3_3_517_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2013.2216"},{"key":"e_1_3_3_518_1","doi-asserted-by":"publisher","DOI":"10.1093\/alcalc\/agae062"},{"key":"e_1_3_3_519_1","doi-asserted-by":"publisher","DOI":"10.1159\/000357865"},{"key":"e_1_3_3_520_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-016-0416-y"},{"key":"e_1_3_3_521_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12571"},{"key":"e_1_3_3_522_1","doi-asserted-by":"publisher","DOI":"10.1067\/mem.2001.119454"},{"key":"e_1_3_3_523_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087366"},{"key":"e_1_3_3_524_1","doi-asserted-by":"publisher","DOI":"10.1159\/000528573"},{"key":"e_1_3_3_525_1","article-title":"Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo L","year":"2017","unstructured":"Sordo L, Barrio G, Bravo MJ, et al (2017) Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies. BMJ 357: j1550.","journal-title":"BMJ"},{"key":"e_1_3_3_526_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1611832"},{"key":"e_1_3_3_527_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.718811"},{"key":"e_1_3_3_528_1","doi-asserted-by":"publisher","DOI":"10.1080\/15622975.2016.1246752"},{"key":"e_1_3_3_529_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1212028"},{"key":"e_1_3_3_530_1","doi-asserted-by":"publisher","DOI":"10.1002\/emp2.12880"},{"key":"e_1_3_3_531_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008940.pub4"},{"key":"e_1_3_3_532_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2676"},{"key":"e_1_3_3_533_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2019.0009"},{"key":"e_1_3_3_534_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd003022"},{"key":"e_1_3_3_535_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108467"},{"key":"e_1_3_3_536_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2020.108059"},{"key":"e_1_3_3_537_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2010.05.014"},{"key":"e_1_3_3_538_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2020.108031"},{"key":"e_1_3_3_539_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.11.1000"},{"key":"e_1_3_3_540_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.1999.9421993.x"},{"key":"e_1_3_3_541_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60349-2"},{"key":"e_1_3_3_542_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.114.149195"},{"key":"e_1_3_3_543_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.1989.tb00737.x"},{"key":"e_1_3_3_544_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2018.17070732"},{"key":"e_1_3_3_545_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2007.11.034"},{"key":"e_1_3_3_546_1","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2015.1110590"},{"key":"e_1_3_3_547_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013790.pub2"},{"key":"e_1_3_3_548_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.631784"},{"key":"e_1_3_3_549_1","volume-title":"The Maudsley Prescribing Guidelines in Psychiatry","author":"Taylor D","year":"2025","unstructured":"Taylor D, Barnes T, Young A (2025) The Maudsley Prescribing Guidelines in Psychiatry, 15th edn. Wiley-Blackwell.","edition":"15"},{"key":"e_1_3_3_550_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013522.pub2"},{"key":"e_1_3_3_551_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109497"},{"key":"e_1_3_3_552_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.138.6.845"},{"key":"e_1_3_3_553_1","first-page":"310","article-title":"Double-blind comparison of desipramine and placebo for treatment of phencyclidine or amphetamine dependence","volume":"67","author":"Tennant FS","year":"1986","unstructured":"Tennant FSJr, Tarver A, Pumphrey E, et al (1986) Double-blind comparison of desipramine and placebo for treatment of phencyclidine or amphetamine dependence. NIDA Research Monograph 67: 310\u2013317.","journal-title":"NIDA Research Monograph"},{"key":"e_1_3_3_554_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013308.pub2"},{"key":"e_1_3_3_555_1","doi-asserted-by":"publisher","DOI":"10.1080\/15622975.2018.1510185"},{"key":"e_1_3_3_556_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101095"},{"key":"e_1_3_3_557_1","doi-asserted-by":"publisher","DOI":"10.1093\/alcalc\/37.6.513"},{"key":"e_1_3_3_558_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01470-2"},{"key":"e_1_3_3_559_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-018-0685-1"},{"key":"e_1_3_3_560_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.1.64"},{"key":"e_1_3_3_561_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007024.pub3"},{"key":"e_1_3_3_562_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030080"},{"key":"e_1_3_3_563_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-024-01424-6"},{"key":"e_1_3_3_564_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0190768"},{"key":"e_1_3_3_565_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2020214"},{"key":"e_1_3_3_566_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mpmed.2024.06.012"},{"key":"e_1_3_3_567_1","doi-asserted-by":"publisher","DOI":"10.64719\/pb.4615"},{"key":"e_1_3_3_568_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2011.01.003"},{"key":"e_1_3_3_569_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2012.08.001"},{"key":"e_1_3_3_570_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2025.102509"},{"key":"e_1_3_3_571_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-019-01091-0"},{"key":"e_1_3_3_572_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2013.05.008"},{"key":"e_1_3_3_573_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-025-01312-x"},{"key":"e_1_3_3_574_1","doi-asserted-by":"publisher","DOI":"10.1002\/wps.21073"},{"key":"e_1_3_3_575_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.0658"},{"key":"e_1_3_3_576_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.15489"},{"key":"e_1_3_3_577_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f174"},{"key":"e_1_3_3_578_1","volume-title":"Smoking cessation and cannabis use: A guide for stop smoking practitioners","author":"Walsh H","year":"2020","unstructured":"Walsh H, Papadakis S, Ross L, et al (2020) Smoking cessation and cannabis use: A guide for stop smoking practitioners. National Centre for Smoking Cessation and Training."},{"key":"e_1_3_3_579_1","doi-asserted-by":"publisher","DOI":"10.2147\/SAR.S433358"},{"key":"e_1_3_3_580_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.167.22.2469"},{"key":"e_1_3_3_581_1","unstructured":"Wedinos (2024) Wedinos Report 2024. Available at: https:\/\/www.wedinos.org\/reports-publications (accessed 17 December 2025)."},{"key":"e_1_3_3_582_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001202"},{"key":"e_1_3_3_583_1","doi-asserted-by":"publisher","DOI":"10.1097\/TA.0b013e31815eb12a"},{"issue":"1","key":"e_1_3_3_584_1","first-page":"123","article-title":"Narrative review: Revised principles and practice recommendations for adolescent substance use treatment and policy","volume":"64","author":"Welsh JW","year":"2025","unstructured":"Welsh JW, Dopp AR, Durham RM, et al (2025) Narrative review: Revised principles and practice recommendations for adolescent substance use treatment and policy. Journal of the American Academy of Child and Adolescent Psychiatry 64(1): 123-142.","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"key":"e_1_3_3_585_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2004.00995.x"},{"key":"e_1_3_3_586_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(21)00029-8"},{"key":"e_1_3_3_587_1","unstructured":"WHO (2019) International Classification of Diseases Eleventh Revision (ICD-11). Available at: https:\/\/icd.who.int\/browse\/2025-01\/mms\/en (accessed 3 October 2025)."},{"key":"e_1_3_3_588_1","unstructured":"WHO (2020) Decade of Healthy Ageing: Plan of Action 2021-2030. World Health Organization. Available at: https:\/\/cdn.who.int\/media\/docs\/default-source\/decade-of-healthy-ageing\/final-decade-proposal\/decade-proposal-final-apr2020-en.pdf?sfvrsn=b4b75ebc_25&download=true (accessed 21 October 2025)."},{"key":"e_1_3_3_589_1","author":"WHO","year":"2024","unstructured":"WHO (2024) Global status report on alcohol and health and treatment of substance use disorders.","journal-title":"Global status report on alcohol and health and treatment of substance use disorders"},{"key":"e_1_3_3_590_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.1984.tb05726.x"},{"key":"e_1_3_3_591_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881115612237"},{"key":"e_1_3_3_592_1","doi-asserted-by":"publisher","DOI":"10.1159\/000113724"},{"key":"e_1_3_3_593_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aax4043"},{"key":"e_1_3_3_594_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2025.2508"},{"key":"e_1_3_3_595_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10112333"},{"key":"e_1_3_3_596_1","doi-asserted-by":"publisher","DOI":"10.1136\/pn-2023-003817"},{"key":"e_1_3_3_597_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.10574"},{"key":"e_1_3_3_598_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000040280"},{"key":"e_1_3_3_599_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2024.100233"},{"key":"e_1_3_3_600_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.13394"},{"key":"e_1_3_3_601_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cobeha.2018.08.004"},{"key":"e_1_3_3_602_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.1003257"},{"key":"e_1_3_3_603_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.13462"},{"key":"e_1_3_3_604_1","doi-asserted-by":"publisher","DOI":"10.2190\/PM.48.2.c"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811251399593","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811251399593","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811251399593","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T05:18:54Z","timestamp":1780463934000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811251399593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":603,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1177\/02698811251399593"],"URL":"https:\/\/doi.org\/10.1177\/02698811251399593","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}